Any current/future new fundraising through debt or equity?

As of the Q1 FY24 call, Valiant Organics reported total debt of around INR 190-195 crores (term loan ~INR 90 crores and short-term ~INR 91-92 crores). The company is not considering taking any significant new debt currently but plans to revisit the need depending on market conditions in a couple of months. Term loans are being repaid as scheduled, with INR 40-45 crores expected to be repaid in FY24 and loans targeted to be fully repaid by FY26. Regarding equity/fundraising from promoters, the management did not comment on any further promoter dilution or stake sale plans due to multiple promot

Any current/future capex/capital investment/strategic investment?

The company is revisiting its CapEx plans due to the current demand slowdown but intends to continue with the projects, possibly delaying some by a quarter or so. CapEx has been substantial over the past four to five years, spread across phases including chlorination, hydrogenation, ammonolysis expansions, PAP (a new Greenfield project), backward integration of OA and PA, OAP ongoing, and Pharma Intermediate project commercialization. No significant new debt is planned currently; peak debt is estimated around INR 190-195 crores, with ongoing repayments targeted to clear term loans by FY26. Inv

Future growth expectations in sales/revenue/volumes?

Revenue guidance for FY24 has been revised down from INR 1,200 crore to INR 800-850 crore due to weak demand and price corrections. (Page 7, 14) Expected degrowth in revenue is around 5-10% for the year, driven by overall demand slowdown. (Page 6) Volume degrowth company-wide is approximately 14-15%, while price decline contributes about 10%. (Page 16) Pharma segment seen as a growth driver; PAP projected at INR 170-180 crore, possibly up to INR 200 crore, lower than earlier estimates. (Page 15) Pharma Intermediate Project recently commercialized and expected to contribute around INR 60-65 cro

Valiant Organics LtdQ1 FY24Chemicals & Petrochemicals

Valiant Organics Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹477P/E: 22.8Market Cap: ₹1.2K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 5

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 5

Revenue guidance for FY24 has been revised down from INR 1,200 crore to INR 800-850 crore due to weak demand and price corrections. (Page 7, 14)
Expected degrowth in revenue is around 5-10% for the year, driven by overall demand slowdown. (Page 6)
Volume degrowth company-wide is approximately 14-15%, while price decline contributes about 10%. (Page 16)
Pharma segment seen as a growth driver; PAP projected at INR 170-180 crore, possibly up to INR 200 crore, lower than earlier estimates. (Page 15)
Pharma Intermediate Project recently commercialized and expected to contribute around INR 60-65 crore yearly, but negligible contribution in current quarter. (Page 15)
Ramp-up of PAP capacity is targeted to reach around 900 MT/month by year-end, conditional on market demand. (Page 12)
Anticipated demand improvement expected in Q3 and Q4, particularly in textile segment; however, near-term demand remains weak. (Pages 6, 10)
Demand for dyes, pigments, and agrochemical segments are subdued. (Page 14)

Margin guidance

Category 3

- The company anticipates a difficult year for FY24 with expected revenue degrowth of around 5-10% due to weak demand and pricing pressures. - EBITDA margins are projected to be between 12-15%, revised down from earlier guidance of 20% because of demand slowdowns in textiles, agrochemicals, and pricing corrections. - Pharma segment expected to grow, but price corrections in PAP products will impact margins; PAP revenue guidance revised down to INR 170-180 crores from INR 300 crores. - Pharma Intermediates segment is in early stages; expected full-year contribution is INR 60-65 crores. - The company expects some demand improvement in Q3 and Q4, but overall scenario remains uncertain. - CapEx plans continue but may see slight delays; peak debt expected around INR 190-195 crores. - Operational efficiencies are being enhanced through renewable energy and automation but employee costs are not expected to decline. Overall, cautious outlook with subdued earnings growth in near term.

See what Valiant Organics Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

As of the Q1 FY24 call, Valiant Organics reported total debt of around INR 190-195 crores (term loan ~INR 90 crores and short-term ~INR 91-92 crores).
The company is not considering taking any significant new debt currently but plans to revisit the need depending on market conditions in a couple of months.
Term loans are being repaid as scheduled, with INR 40-45 crores expected to be repaid in FY24 and loans targeted to be fully repaid by FY26.
Regarding equity/fundraising from promoters, the management did not comment on any further promoter dilution or stake sale plans due to multiple promoters involved; no specific future equity fundraising was announced.
The company is focusing on planned CapEx with possible slight postponement but no major changes to expansion plans.

Order book

The transcript does not provide specific details about the current or expected order book or pending orders for Valiant Organics Ltd. However, some relevant points can be inferred: - Demand is currently significantly impacted with volume drops of around 14-15% and price reduction around 10% at the company level. - Capacity utilization is running at about 50%, with some products (e.g., PAP) affected by shutdowns. - Outlook for Pharma intermediates and OAP is cautious; OAP commercialization is delayed due to quality issues. - The company expects some turnaround in the market in Q3 and Q4, but overall demand remains weak in Q1 and Q2. - No explicit quantitative guidance on order book or pending orders was mentioned during the call. If you need detailed order book data, it may be best to refer to official company filings or directly contact the company.

See what Valiant Organics Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is revisiting its CapEx plans due to the current demand slowdown but intends to continue with the projects, possibly delaying some by a quarter or so.
CapEx has been substantial over the past four to five years, spread across phases including chlorination, hydrogenation, ammonolysis expansions, PAP (a new Greenfield project), backward integration of OA and PA, OAP ongoing, and Pharma Intermediate project commercialization.
No significant new debt is planned currently; peak debt is estimated around INR 190-195 crores, with ongoing repayments targeted to clear term loans by FY26.
Investments include introduction of renewable captive energy plant (2.2 MW wind power) expected to yield INR 2.5-3 crores annual savings.
Process automation through DCS systems is being implemented to improve efficiency.
No major new strategic investments or expansions have been announced; focus is on ramping up and stabilizing current projects.

Track Valiant Organics Ltd — get its next earnings analysis in your feed

How does Valiant Organics Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisValiant Organics Ltd

Rev 5Mar 3

See where Valiant Organics Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Valiant Organics Ltd rank in Chemicals & Petrochemicals?

Compare Valiant Organics Ltd against every Chemicals & Petrochemicals company (Q1 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Valiant Organics Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →